Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a report released on Friday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I upgraded Enlivex Therapeutics to a strong-buy rating in a report on Tuesday, August 27th.

Enlivex Therapeutics Stock Up 3.8 %

NASDAQ:ENLV opened at $1.64 on Friday. The firm has a market capitalization of $35.11 million, a P/E ratio of -1.18 and a beta of 1.03. The company has a fifty day moving average of $1.34 and a 200 day moving average of $1.76. Enlivex Therapeutics has a 52 week low of $1.15 and a 52 week high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings data on Friday, August 30th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. As a group, analysts anticipate that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Investors Weigh In On Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. XTX Topco Ltd acquired a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned 0.12% of Enlivex Therapeutics at the end of the most recent reporting period. 1.02% of the stock is currently owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.